Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

Schally AV, Block NL, Rick FG.

Asian J Androl. 2015 Nov-Dec;17(6):925-8. doi: 10.4103/1008-682X.152819.

3.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):725-30. doi: 10.1016/j.bmcl.2013.12.120.

4.

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

5.

Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.

Ziegler CG, Ullrich M, Schally AV, Bergmann R, Pietzsch J, Gebauer L, Gondek K, Qin N, Pacak K, Ehrhart-Bornstein M, Eisenhofer G, Bornstein SR.

Mol Cell Endocrinol. 2013 May 22;371(1-2):189-94. doi: 10.1016/j.mce.2012.12.011.

6.

Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity.

Xu P, Chen J, Chen Z, Zhou S, Hu P, Chen X, Huang M.

PLoS One. 2012;7(5):e37051. doi: 10.1371/journal.pone.0037051.

7.

Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.

Taheri A, Dinarvand R, Atyabi F, Ahadi F, Nouri FS, Ghahremani MH, Ostad SN, Borougeni AT, Mansoori P.

Int J Mol Sci. 2011;12(7):4591-608. doi: 10.3390/ijms12074591.

8.

Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

Guo H, Lu J, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioconjug Chem. 2011 Aug 17;22(8):1682-9. doi: 10.1021/bc200252j.

10.

Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.

Tietze LF, Panknin O, Krewer B, Major F, Schuberth I.

Int J Mol Sci. 2008 May;9(5):821-37. doi: 10.3390/ijms9050821.

11.

Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.

Majumdar S, Tejo BA, Badawi AH, Moore D, Krise JP, Siahaan TJ.

Mol Pharm. 2009 Mar-Apr;6(2):396-406. doi: 10.1021/mp800120t.

12.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

Buchholz S, Keller G, Schally AV, Halmos G, Hohla F, Heinrich E, Koester F, Baker B, Engel JB.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10403-7.

14.

A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy.

Wang X, Krebs LJ, Al-Nuri M, Pudavar HE, Ghosal S, Liebow C, Nagy AA, Schally AV, Prasad PN.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11081-4.

15.
16.

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794-9.

17.

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Kovacs M, Schally AV, Nagy A, Koppan M, Groot K.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1420-5.

18.
Items per page

Supplemental Content

Support Center